Fortrea Holdings Inc Dossier
Qualitative Analysis
Business overview
Fortrea Holdings Inc. (NASDAQ: FTRE) is a leading global contract research organization (CRO) providing comprehensive clinical development and consulting solutions. Spun off from Laboratory Corporation of America Holdings (Labcorp) in mid-2023, Fortrea operates as an independent, publicly traded company. The company specializes in Phase I through Phase IV clinical trial management, clinical pharmacology, and patient access solutions. Fortrea serves emerging and large biopharmaceutical, biotechnology, medical device, and diagnostic companies globally, utilizing flexible delivery models including full-service, functional service provider (FSP), and hybrid structures. With a workforce of approximately 14,300 employees operating across roughly 100 countries, Fortrea leverages three decades of clinical research experience to streamline drug development and accelerate life-changing therapies to patients.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Unveiling of an AI-enhanced suite of solutions built on the Xcellerate platform designed to automate clinical trial workflows, streamline oversight, and deliver near-real-time, role-based insights across clinical pharmacology, development, and medical device programs.
Expected impact: Enables sponsors, investigator sites, and project teams to run smarter, more integrated trials with greater predictability, agility, and quality.
Streamlining operations to focus exclusively on clinical development phases 1 through 4, supported by the divestiture of non-core Enabling Services assets and utilizing net proceeds to pay down outstanding debt.
Expected impact: Improves financial flexibility, reduces interest expenses, and sharpens operational focus on organic growth in core clinical trial management.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Aims to streamline development and accelerate timelines for advanced cell and gene therapies by combining Fortrea's global clinical trial reach with SCTbio's manufacturing capabilities.
Terms: Not publicly disclosed